The Leader in Dispensing Innovation

This presentation was posted to the AptarGroup web site on December 18, 2008

and information contained in it is relevant for that date. AptarGroup is under no

obligation to update the information contained in this presentation.

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs as well as assumptions made by and information currently

available to management. Accordingly, the Company’s actual results

Forward-Looking Statements

2

available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such

forward-looking statements due to known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-K’s and 10-Q’s. Readers are

cautioned not to place undue reliance on forward-looking statements.

Our Story

• Leader of the “dispensing systems” niche of the packaging industry

• Adding value to the world’s best knownproducts

3

products

• Providing convenience to consumers everyday

• Diversified portfolio– Products

– Markets

– Geographical Presence

Our Story

• Strong long-term financialperformer

• 42 consecutive years of revenue growth

4

• An industry leader in operating margins

• Strong balance sheet

• Experienced, focused management team

Our Expertise

• Providing creative solutions

• Design and prototyping

5

• Precision injection molding

• High speed assembly

• Clean-room environments for pharmaceutical dispensing systems

15%

11%Pumps

Dispensing

Our Products

6

50%

24%

15% DispensingClosures

Valves

Other

% of 2007 Annual Sales

Our Customers

ASTRAZENECA

7

Company names and/or trademarks used in this presentation are the property of their respective owners and are used for identification purposes only

ESTÉE LAUDER

COTY

53% 21%

Our Segments

41%

2007

Sales

26%

Beauty & Home Pharma Closures

Segment Income*

39%

20%

* Income before taxes, interest, and stock option and corporate expenses

8

Our Presence

9

Principal locations

ROW

Sales by Region

10

Europe 63%U.S. 26% 11%

ROW

% of 2007 Annual Sales

Sales Growth

7711

17

114

20

30

YOY Growth Rates

Currency Effects

CAGR

Core 7.0%

Currency 1.7%

Acq 2.7%

Rptd 11.4%

(4)(7)

1084

992

3126

(2)

7

17

11

2

7

2

114

-10

0

10

'99 '00 '01 '02 '03 '04 '05 '06 '07YOY Growth Rates

Core Currency Acq

% Ranges

Core 2-12%

Currency (7)-11%

Acq 0-14%

Rptd 1-20%

11

Competitive Environment

Pumps Valves Pumps Valves

AptarGroup X X X X X

Public

Rexam X X X

Consort Medical (Bespak) X

PharmaBeauty & HomeClosures

12

Consort Medical (Bespak) X

3M X

MeadWestvaco - Calmar X X

Private

Precision X

Summit X

Coster X X

Lindal X

PAI Partners X

Berry Plastics X

Strong Long-term Financial

Performance

Sales

$0

$500

$1,000

$1,500

$2,000$ in millions

≈ 12% CAGR

13

$0'93 '95 '97 '99 '01 '03 '05 '07

Net Income

$0

$50

$100

$150

'93* '95 '97 '99 '01 '03 '05 '07

$ in millions

14% CAGR

* Before cumulative effect of change in accounting for income taxes

** Beginning in 2006, includes net expense for stock options

Strong Long-term Financial

Performance

Free Cash Flow

$100

$150

$ in millions

14

$0

$50

'93

'95

'97

'99

'01

'03

'05

'07

$ in millions

Note: Free Cash Flow = Cash Flow From Operations – Capital Expenditures

Third Quarter 2008

$485.7 $532.2

$500

$600

$ in millions

Revenue

$0.56* $0.57

$0.50

$0.60

$0.70

EPS

15

$200

$300

$400

$ in millions

Q3 2007 Q3 2008

Impact of Exchange Rate Changes = +7%

$0.20

$0.30

$0.40

Q3 2007 Q3 2008

* Q3 2007 earnings per share include $.03 per share positive effect from tax law changes in Germany.

Year-to-Date 2008

$1,408.4$1,615.8

$1,400

$ in m

illions

Revenue

$1.48*

$1.72

$1.40

EPS

16

$200

$800

$ in m

illions

YTD 2007 YTD 2008

Impact of Exchange Rate Changes = +9%

$0.20

$0.80

YTD 2007 YTD 2008

* YTD 2007 earnings per share include $.03 per share positive effect from tax law changes in Germany.

Strong Balance Sheet

• Net Debt to Net Capital = 8%

• Annual dividend = $.60 per share

17

• Repurchased approx 535,000 shares in Q3

• Remaining shares authorized for repurchase = 4.5 million

52%

Beauty & Home

YTD 2008

Sales Segment Income

36%

18

Anticipated long-term annual core sales growth rate: 4-7%

Beauty & Home Segment

Fragrance/Cosmetic 60%

Personal Care 32%

Sales By Market (% of 2007 Sales)

19

Personal Care 32%

Household 5%

Other 3%

Segment Total 100%

Beauty & Home Segment

($ in millions) Q3 2007 Q3 2008

Net Sales $258.6 $271.7 +5%

Income $25.6 $21.7 -15%

Profitability 9.9% 8.0%

20

NET SALES: Impact From Changes in Exchange Rates = +6% Q3 and 9% YTD

Profitability 9.9% 8.0%

YTD 2007 YTD 2008

Net Sales $750.8 $844.3 +12%

Income $78.1 $77.9 ---

Profitability 10.4% 9.2%

• Sun Screens, Organics, and men’s grooming

• Samples

• Reduction in package sizes

Beauty & Home Trends

• Reduction in package sizes(Travel sizes, single-use, cost saving/smaller containers)

• Input cost pressure

• Economic uncertainty = customers delay orders

21

Innovative Advantages

• Sampling systems

• Bag-on-valves

22

• Preservative-free “airless” systems

• Decorative technologies

Closures Segment

YTD 2008

Sales

26%

Segment Income

17%

23

Anticipated long-term annual core sales growth rate: 5-10%

Closures Segment

Personal Care 60%

Food/Beverage 27%

Sales By Market (% of 2007 Sales)

24

Food/Beverage 27%

Household 10%

Other 3%

Segment Total 100%

Closures Segment

($ in millions) Q3 2007 Q3 2008

Net Sales $126.5 $142.4 +13%

Income $12.5 $12.6 +1%

Profitability 9.9% 8.9%

25

NET SALES: Impact from changes in exchange rates = +7% Q3 and YTD

Profitability 9.9% 8.9%

YTD 2007 YTD 2008

Net Sales $368.0 $420.9 +14%

Income $39.8 $36.7 -8%

Profitability 10.8% 8.7%

• Conversion from screw-off caps to dispensing closures

• Smaller packages

Closures Trends

• Package differentiation(inverted packages, easy-open jar lids )

• Input cost pressure

• Economic uncertainty = Customers delay orders

26

Innovative Advantages

• Silicone valve technology

• Precision dispensing

27

• High-efficiency molding

• Bi-injection molding

22%

Pharma Segment

47%YTD 2008

Sales Segment Income

28

Anticipated long-term annual core sales growth rate: 6-10%

Pharma Segment

($ in millions) Q3 2007 Q3 2008

Net Sales $100.6 $118.1 +17%

Income $29.4 $34.4 +17%

Profitability 29.2% 29.1%

29

NET SALES:Impact From Changes in Exchange Rates =+7% for Q3 and 11% YTD

YTD 2007 YTD 2008

Net Sales $289.6 $350.5 +21%

Income $78.4 $99.3 +27%

Profitability 27.1% 28.3%

Pharma Trends

• Rising number of allergy, asthma and pulmonary conditions and treatments

• Major pharmaceutical players seek alternative drug delivery devices

30

alternative drug delivery devices

• Increasing use of generics in the U.S.

• Developing markets opening up opportunities

• Soft economic conditions could adversely impact certain non-respiratory categories

Innovative Advantages

• Progressive delivery technologies(dose indicators, dry powder, patient-independent)

• Clean-room manufacturing

31

• Clean-room manufacturing

• In-house elastomer expertise

• Laboratory services

Summary

• Market demands convenience and differentiation

• Committed to being the innovative leader

32

• Diversity shields us from short-term market or geographic pullbacks

• Food/beverage still opening up

• Growth opportunities in the pharmaceutical market

The Leader in Dispensing Innovation

www.aptargroup.com